GW27-e0348 Long Term Comparison between Novel Fully Bioresorbable Scaffolds and Drug-Eluting Stents: A Twenty-Four-Month Study in Porcine Coronary Arteries

Gao, Feng; Xiao, Jing; Qin, Chaoshi; Zhao, Lu; Li, Jun; Zheng, Xiang; Liu, Shuzhong; Wu, Tingting; Jiang, Xuejun

doi:10.1016/j.jacc.2016.07.211

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The third generation of DES belongs to the bioresorbable drug-eluting vascular scaffolds (BVS), which disappear or degrade completely after a certain time in the vessel [164][165][166][167][168]. Just as metal DES, BVS have the advantage of no long-term limitations of permanent vessel caging and possible malapposition (incomplete stent apposition), significantly reducing risks of late restenosis, neoatherosclerosis, thrombosis, and local inflammation [169][170][171][172][173][174][175].…”

Section: General Aspectsmentioning

confidence: 99%

Recent Advances in Manufacturing Innovative Stents

et al. 2020

View full text Add to dashboard Cite

Cardiovascular diseases are the most distributed cause of death worldwide. Stenting of arteries as a percutaneous transluminal angioplasty procedure became a promising minimally invasive therapy based on re-opening narrowed arteries by stent insertion. In order to improve and optimize this method, many research groups are focusing on designing new or improving existent stents. Since the beginning of the stent development in 1986, starting with bare-metal stents (BMS), these devices have been continuously enhanced by applying new materials, developing stent coatings based on inorganic and organic compounds including drugs, nanoparticles or biological components such as genes and cells, as well as adapting stent designs with different fabrication technologies. Drug eluting stents (DES) have been developed to overcome the main shortcomings of BMS or coated stents. Coatings are mainly applied to control biocompatibility, degradation rate, protein adsorption, and allow adequate endothelialization in order to ensure better clinical outcome of BMS, reducing restenosis and thrombosis. As coating materials (i) organic polymers: polyurethanes, poly(ε-caprolactone), styrene-b-isobutylene-b-styrene, polyhydroxybutyrates, poly(lactide-co-glycolide), and phosphoryl choline; (ii) biological components: vascular endothelial growth factor (VEGF) and anti-CD34 antibody and (iii) inorganic coatings: noble metals, wide class of oxides, nitrides, silicide and carbide, hydroxyapatite, diamond-like carbon, and others are used. DES were developed to reduce the tissue hyperplasia and in-stent restenosis utilizing antiproliferative substances like paclitaxel, limus (siro-, zotaro-, evero-, bio-, amphi-, tacro-limus), ABT-578, tyrphostin AGL-2043, genes, etc. The innovative solutions aim at overcoming the main limitations of the stent technology, such as in-stent restenosis and stent thrombosis, while maintaining the prime requirements on biocompatibility, biodegradability, and mechanical behavior. This paper provides an overview of the existing stent types, their functionality, materials, and manufacturing conditions demonstrating the still huge potential for the development of promising stent solutions.

show abstract